Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Ketogenic Diet with Letrozole in Treating Patients with Estrogen Receptor Positive Breast Cancer

Breast

This early phase I trial studies how well ketogenic diet with letrozole works in treating patients with estrogen receptor positive breast cancer. Estrogen receptor positive breast cancer has special proteins on it, called estrogen receptors, that allow it to grow when exposed to estrogen. A ketogenic diet (low calorie, low carbohydrate) may help normalize abnormally high insulin levels that in turn may slow the growth of cancer cells. Letrozole may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.The purpose of this study is to learn if the combination of a 2 week ketogenic diet in combination with letrozole can help slow the growth of tumors.
Breast
Early I
Rexer, Brent
NCT03962647
VICCBRE18108

Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies

Multiple Cancer Types

This phase Ib trial studies the side effects and best dose of venetoclax and selinexor and how well they work in treating patients with high risk hematologic malignancies such as diffuse large B-cell lymphoma, multiple myeloma, or acute myeloid leukemia that have come back (recurrent) or do not respond to treatment (refractory). Venetoclax functions by inhibiting or slowing down a protein in the body called bcl-2, which is involved in slowing down the normal process by which old cells in the body are cleared (called apoptosis). Selinexor functions by trapping “tumor suppressing proteins” within the cell and causing the cancer cells to die or stop growing. This study examines the effects, if any, of selinexor and venetoclax on high risk hematologic malignancies and on the body, including any side-effects.
Hematologic, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome, Phase I
I
Byrne, Michael
NCT03955783
VICCHEM1755

Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence

Multiple Cancer Types

This phase II trial studies the side effects of ifetroban in treating patients with malignant solid tumors that are at high risk of coming back after treatment (recurrent) and spreading throughout the body (metastatic). Platelets are a type of blood cells that help with clotting. Cancer cells stick to platelets and ride on them to get to different parts of the body. Drugs, such as ifetroban, may help these platelets become less "sticky," and reduce the chance of cancer cells spreading to other places in the body.
Breast, Esophageal, Gastric/Gastroesophageal, Lung, Non Small Cell, Pancreatic, Small Cell
II
Mayer, Ingrid
NCT03694249
VICCMD1854

Afatinib and Necitumumab in Treating Patients with EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Multiple Cancer Types

This phase I trial studies the side effects and best dose of afatinib and necitumumab and to see how well they work in treating patients with EGFR mutation positive non-small cell lung cancer that has spread to other places in the body (advanced or metastatic). Afatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as necitumumab, may interfere with the ability of tumor cells to grow and spread. Giving afatinib and necitumumab may work better in treating patients with EGFR mutation positive non-small cell lung cancer.
Lung, Non Small Cell
I
York, Sally
NCT03054038
VICCTHO1684

Capecitabine and Radiation Therapy after Surgery in Treating Patients with Non-Metastatic Invasive Breast cancer

Multiple Cancer Types

This phase I trial studies how well capecitabine and radiation therapy after surgery work in treating patients with invasive breast cancer that has not spread to other places in the body. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving capecitabine and radiation therapy together may kill more tumor cells in patients with invasive breast cancer compared to capecitabine or radiation therapy alone.
Breast, Phase I
I
Chak, Bapsi
NCT03958721
VICCBREP1898

Glutaminase Inhibitor CB-839, Panitumumab, and Irinotecan Hydrochloride in Treating Patients with Metastatic and Refractory RAS Wildtype Colorectal Cancer

Multiple Cancer Types

This phase I / II trial studies the best dose and side effects of glutaminase inhibitor CB-839 and how well it works with panitumumab and irinotecan hydrochloride in treating patients with RAS wildtype colorectal cancer that has spread to other places in the body and does not respond to treatment. Glutaminase inhibitor CB-839 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as panitumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving glutaminase inhibitor CB-839 with panitumumab and irinotecan hydrochloride may work better in treating patients with colorectal cancer.
Colon, Rectal
I/II
Berlin, Jordan
NCT03263429
VICCGI1703

Early Palliative Care in Improving Recovery and Quality of Life in Patients with Cancer Undergoing Abdominal Surgery, the SCOPE Trial

Multiple Cancer Types

This trial studies early palliative care in improving recovery and quality of life in patients with cancer undergoing abdominal surgery. Frequently people diagnosed with cancer experience physical and emotional symptoms during the course of their disease. Introduction to a team of clinicians that specialize in the lessening of many of these distressing symptoms may improve overall care. This team of clinicians is called the palliative care team and they focus on ways to improve pain and other symptom management (i.e. shortness of breath, fatigue, anxiety, etc.) and to assist patients and their families in coping with the emotional, social, and spiritual issues associated with a cancer diagnosis. This study is being done to see if receiving palliative care earlier is more useful compared to receiving palliative care late in the course of illness.
Bladder, Colon, Gastrointestinal, Gynecologic, Liver, Ovarian, Pancreatic, Supportive Care, Urologic
N/A
Shinall, Ricky
NCT03436290
VICCSUPP1971

Nivolumab with or without Ipilimumab in Treating Patients with Metastatic or Advanced Kidney Cancer

Kidney (Renal Cell)

This phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with kidney cancer that has spread to other places in the body (metastatic or advanced). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Kidney (Renal Cell)
II
Beckermann, Kathryn
NCT03126331
VICCURO19140

Galunisertib and Paclitaxel in Treating Patients with Metastatic Androgen Receptor Negative or Triple Negative Breast Cancer

Breast

This phase I trial studies the side effects and best dose of galunisertib when given together with paclitaxel in treating patients with androgen receptor negative or triple negative breast cancer that has spread to other places in the body. Some tumors need growth factors, which are made by the body's white blood cells, to keep growing. Galunisertib may interfere with growth factors and help cause tumor cells to die. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving glunisertib together with paclitaxel may kill more tumor cells.
Breast
I
Abramson, Vandana
NCT02672475
VICCBRE1557

Covered Metal Stents versus Uncovered Metal Stents for the Treatment of Jaundice due to Pancreatic Cancer, Cholangiocarcinoma, or Other Metastatic Malignancies

Multiple Cancer Types

This trial studies how well covered metal stents versus uncovered metal stents work in treating patients with jaundice due to pancreatic cancer, cholangiocarcinoma (bile duct), or other malignancies that have spread to other places in the body (metastatic). Jaundice can make the skin and urine appear very yellow and cause itching throughout the body. Pancreatic cancer, cholangiocarcinoma, or other metastatic malignancies can cause jaundice by blocking the bile duct. The bile duct is a tube-like structure that drains the liver. To maintain an opening in the bile duct, a stent is placed. Uncovered self-expanding metal biliary stents have a bare metal scaffold that the tissue tends to grow into and thus blocks the stent from draining, while covered self-expanding metal biliary stents have a polyurethane coating that may prevent the tissue from growing into the stent and thus blocking the stent. It is not yet known whether covered or uncovered metal stents may work better in treating patients with jaundice.
Gastrointestinal, Pancreatic
N/A
Yachimski, Patrick
NCT01905384
VICCGI1984

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: